Share this article
FRANKLIN LAKES, N.J., March 4, 2021 /PRNewswire/
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired GSL Solutions, Inc. ( GSL ), a privately-held company that develops smart medication devices for the storage and tracking of controlled substances and patient specific medications that improve the security, efficiency and compliance of medication storage, as well as analytic capabilities to further improve inventory management, including of controlled substances, regulatory compliance and patient safety.
This acquisition expands BD s advanced medication management capabilities to further meet the needs of retail pharmacies, including those in outpatient settings.
Research Antibodies Market Size to Reach USD 5,325 8 Million by 2027 | Increasing R&D Activities in the Fields of Oncology, Neurobiology, and Stem Cells will Drive the Industry Growth, says Emergen Research
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Major companies in the diabetes care devices market include Roche; Medtronic; J&J; Abbott and Becton, Dickinson and Company. The global diabetes care devices market is expected to grow from $39.New York, Feb. 24, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report "Diabetes Care Devices Global Market Report 2021: COVID 19 Implications and Growth to 2030" - https://www.reportlinker.com/p06027758/?utm source=GNW 51 billion in 2020 to $41.84 billion in 2021 at a compound annual growth rate (CAGR) of 5.9%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $54.31 billion in 2025 at a CAGR of 7%.The diabetes care devices market consists of sales of diabetes care devices and related services by entities (organizations, sole traders and partnerships) that produce diabetes care devices used to monitor
Share this article
Share this article
FRANKLIN LAKES, N.J., Feb. 22, 2021 /PRNewswire/ BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Scanwell Health, a leader in smartphone-enabled at-home medical tests, today announced a collaboration to create an at-home rapid test for SARS-CoV-2 using a BD antigen test and the Scanwell Health mobile app.
As part of the collaboration, BD plans to produce a lateral flow antigen test and pair it with the Scanwell Health mobile app. The app is expected to provide step-by-step instructions on how to collect and transfer a nasal swab sample and use the mobile device s camera to analyze and interpret results. The test result will be displayed onscreen, and the companies are also planning to develop functionality to assist in automated reporting to public health agencies. This approach is intended to provide an efficient and scalable rapid antigen home testing solution.
vimarsana © 2020. All Rights Reserved.